Squarepoint
TBPH icon

Squarepoint’s Theravance Biopharma TBPH Stock Holding History

Squarepoint’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-67,355
Closed -$1.26M – 4953
2025
Q4 		$1.26M Buy
67,355
+20,605
+44% +$342K ﹤0.01% 2410
2025
Q3 		$683K Buy
46,750
+33,428
+251% +$422K ﹤0.01% 2970
2025
Q2 		$147K Sell
13,322
-10,445
-44% -$102K ﹤0.01% 4068
2025
Q1 		$212K Sell
23,767
-23,401
-50% -$218K ﹤0.01% 3977
2024
Q4 		$444K Sell
47,168
-51,783
-52% -$471K ﹤0.01% 3826
2024
Q3 		$798K Sell
98,951
-17,305
-15% -$150K ﹤0.01% 2776
2024
Q2 		$986K Buy
+116,256
New +$1.05M ﹤0.01% 2567
2024
Q1 		– Sell
-52,054
Closed -$585K – 4598
2023
Q4 		$585K Buy
+52,054
New +$524K ﹤0.01% 2890
2023
Q3 		– Sell
-48,706
Closed -$504K – 4232
2023
Q2 		$504K Sell
48,706
-1,070
-2% -$11.8K ﹤0.01% 2616
2023
Q1 		$540K Sell
49,776
-18,503
-27% -$196K ﹤0.01% 2256
2022
Q4 		$766K Buy
68,279
+13,553
+25% +$142K ﹤0.01% 2015
2022
Q3 		$555K Buy
54,726
+35,741
+188% +$335K ﹤0.01% 2154
2022
Q2 		$172K Buy
+18,985
New +$175K ﹤0.01% 2519
2022
Q1 		– Sell
-15,971
Closed -$176K – 3503
2021
Q4 		$176K Sell
15,971
-19,255
-55% -$168K ﹤0.01% 2757
2021
Q3 		$261K Buy
+35,226
New +$394K ﹤0.01% 2329
2020
Q4 		– Sell
-49,919
Closed -$738K – 3254
2020
Q3 		$738K Buy
49,919
+38,069
+321% +$713K 0.01% 1168
2020
Q2 		$249K Buy
+11,850
New +$304K ﹤0.01% 1713
2019
Q4 		– Sell
-49,622
Closed -$967K – 2790
2019
Q3 		$967K Sell
49,622
-6,439
-11% -$130K 0.01% 1263
2019
Q2 		$915K Buy
56,061
+38,656
+222% +$783K 0.01% 1315
2019
Q1 		$395K Buy
+17,405
New +$441K ﹤0.01% 1612
2016
Q3 		– Sell
-12,300
Closed -$279K – 1248
2016
Q2 		$279K Buy
+12,300
New +$266K 0.02% 772

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint's TBPH Position: Q1 2026 in Review

Squarepoint sold out of Theravance Biopharma (TBPH) in Q1 2026, closing a stake of 67,355 shares — an estimated $1.26M sold.

Squarepoint first reported a position in TBPH in Q2 2016 and held it in 21 quarters. The position peaked at $1.26M in Q4 2025. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • Squarepoint reported no remaining Theravance Biopharma position as of Q1 2026 after selling out during the quarter.
  • Squarepoint sold 67,355 Theravance Biopharma shares in Q1 2026, an estimated $1.26M.
  • Squarepoint first reported a position in Theravance Biopharma in Q2 2016 and held it in 21 quarters.
  • Squarepoint's Theravance Biopharma position peaked at $1.26M in Q4 2025.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.